Article

Correction

A recent "Hands On" article in Urology Times ("Post-prostate biopsy infection: Incidence and preventive steps," July 2011, pages 40-41) included a Figure that contained an error.

A recent "Hands On" article in Urology Times ("Post-prostate biopsy infection: Incidence and preventive steps," July 2011, pages 40-41) included a Figure that contained an error.

The Figure inadvertently transposed the terms "Fluoroquinolone-resistant" and "Fluoroquinolone-sensitive."

For the complete article, which includes the corrected Figure, please see urologytimes.com/HandsOnbiopsyinfection.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Landon Trost, MD, answers a question during a Zoom video interview
Related Content
Study finds geographic disparities in MRI use in prostate cancer
March 27th 2025

Study finds geographic disparities in MRI use in prostate cancer

Hannah Clarke
The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
March 26th 2025

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

Andrea Necchi, MD Hannah Clarke
"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL
"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
FDA approves gepotidacin for uncomplicated UTI
March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke
The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.
© 2025 MJH Life Sciences

All rights reserved.